Showing 181-190 of 1378 results for "".
- DefenAge's D2-Minute Reveal Masque Named NewBeauty's 2019 Best Brightening Maskhttps://practicaldermatology.com/news/defenages-d2-minute-reveal-masque-named-newbeautys-2019-best-brightening-mask/2459973/DefenAge’s D2-Minute Reveal Masque is the
- Burt's Bees Sensitive Skincare Line Awarded National Eczema Association Seal of Acceptancehttps://practicaldermatology.com/news/burts-bees-sensitive-skincare-line-awarded-national-eczema-association-seal-of-acceptance/2457892/The National Eczema Society (NEA) has awarded Burt's Bees' Sensitive skin care line the NEA's Seal of Acceptance, which maintains rigorous standards for approval. The Sensitive skin care line includes Burt's Bees Sensitive Facial Cleanser, Burt's Bees Sensitive Eye Cream, Burt
- Alastin Skincare's INhance Post-Injection Serum Reduces Bruisinghttps://practicaldermatology.com/news/alastin-skincares-inhance-post-injection-serum-reduces-bruising/2460419/Alastin’s Skincare’s INhance Post-Injection Serum with TriHex Technology can help reduce post-injection bruising and swelling, according to a report inthe Journal of Drugs in Dermatology. In
- HydraFacial Company Partners With Alastin Skincarehttps://practicaldermatology.com/news/hydrafacial-company-partners-with-alastin-skincare/2459931/Alastin Skincare’s TriHex-Pro Skin Booster Serum is now available at HydraFacial providers across the United States. The key ingredient in the TriHex-Pro Skin Booster Serum is Alastin's proprieta
- FDA Advisory Arm Backs XELJANZ for PsAhttps://practicaldermatology.com/news/fda-advisory-arm-backs-xeljanz-for-psa/2458098/The United States Food and Drug Administration’s (FDA) Arthritis Advisory Committee recommends the approval of Pfizer's XELJANZ® (tofacitinib) for the treatment of adults with active psoriatic arthritis (PsA). The Arthritis Advisory Commit
- Do the FDA's Proposed Regulations on Tanning Bed Use Go Far Enough?https://practicaldermatology.com/news/do-the-fdas-proposed-regulations-on-tanning-bed-use-go-far-enough/2458646/As the comment period on the US Food and Drug Administration’s proposal to restrict tanning bed use winds down, researchers are weighing in on the proposal's merits and potential shortfalls. Investigators
- Almirall and University of Michigan Collaborate to Gain Understanding of Disease Drivers in Hidradenitis Suppurativahttps://practicaldermatology.com/news/almirall-and-university-of-michigan-collaborate-to-gain-understanding-of-disease-drivers-in-hidradenitis-suppurativa/2461107/Almirall, S.A. entered into a collaboration agreement with the University of Michigan to accelerate the understanding of the factors that trigger hidradenitis suppurativa. Through this partnership, Almirall's expertise in skin diseases will be combined with the knowledge of the Dermatolo
- GHG Audit Shows Key Emission Sources in Dermatology Practicehttps://practicaldermatology.com/news/ghg-audit-shows-key-emission-sources-dermatology-practice/2470894/A new study has identified scope 3 emissions, particularly purchased goods and services, as the largest contributor to the carbon footprint of an outpatient dermatology clinic, accounting for 51.1% of total greenhouse gas (GHG) emissions. The research, conducted at a University of Pennsylv
- New AD Research Indicates 'New Standards of Care'https://practicaldermatology.com/news/new-ad-research-indicates-new-standards-care/2468544/The bar has been raised for atopic dermatitis (AD). That was the message in “Is EASI 75 Good Enough or Can We Do Better? Elevating Efficacy and Long-Term Safety With JAK Inhibitors in Moderate-to-Severe Atopic Dermatitis,” a presentation from Drs. Christopher Bunick, Brad Glick, and Alexandra Gol
- Ruxolitinib cream 1.5% Demonstrates Tolerability, Safety Over 52 Weeks in Childrenhttps://practicaldermatology.com/news/ruxolitinib-cream-15-demonstrates-tolerability-safety-over-52-weeks-children/2467044/Ruxolitinib cream 1.5% demonstrated consistently good tolerability and safety over 52 weeks in children 2 to 11 years old with extensive moderate-to-severe atopic dermatitis (AD) in a study presented this month at the Revolutionizing Atopic Dermatitis (RAD) Conference in Chicago, Illinois.